Immunology of Infectious Disease News Volume 9.39 | Oct 13 2021

    By
    Justin.choi
    -
    0
    35






    2021-10-13 | IIDN 9.39


    Immunology of Infectious Disease News by STEMCELL Technologies
    Vol. 9.39 – 13 October, 2021
    TOP STORY

    Cyclic CMP and Cyclic UMP Mediate Bacterial Immunity against Phages

    Scientists reported that cCMP and cUMP were second messengers functioning in bacterial immunity against viruses. They discovered a family of bacterial pyrimidine cyclase enzymes that specifically synthesized cCMP and cUMP following phage infection.
    [Cell]

    AbstractGraphical Abstract

    SepMate™ PBMC Isolation
    PUBLICATIONSRanked by the impact factor of the journal

    The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate

    Investigators characterized the immunology of neonates born to mothers with confirmed SARS-CoV-2 infection during pregnancy. They showed that maternal SARS-CoV-2 infection affected the neonatal immune system.
    [Nature Immunology]

    Full Article

    Characterization of Humoral and SARS-CoV-2 Specific T Cell Responses in People Living with HIV

    The authors showed that the majority of people living with HIV with ART suppressed HIV viral load, mounted a detectable adaptive immune response to SARS-CoV-2.
    [Nature Communications]

    Full Article

    Increased Lethality in Influenza and SARS-CoV-2 Coinfection Is Prevented by Influenza Immunity but Not SARS-CoV-2 Immunity

    Researchers examined the disease outcome of influenza A virus and SARS-CoV-2 coinfection in K18-hACE2 mice.
    [Nature Communications]

    Full Article

    Nuclear-Localized Human Respiratory Syncytial Virus NS1 Protein Modulates Host Gene Transcription

    Investigators observed NS1 partitioning into the nucleus of RSV-infected cells, including the human airway epithelium.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Role of miR-2392 in Driving SARS-CoV-2 Infection

    Scientists showed that miR-2392 was key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia as well as promoting many symptoms associated with COVID-19 infection.
    [Cell Reports]

    AbstractGraphical Abstract

    Safety, Tolerability and Antiviral Activity of the Antisense Oligonucleotide Bepirovirsen in Patients with Chronic Hepatitis B: A Phase II Randomized Controlled Trial

    Investigators evaluated the safety and activity of an antisense oligonucleotide targeting hepatitis B virus (HBV) RNA in both treatment-naïve and virally suppressed individuals with chronic HBV infection.
    [Nature Medicine]

    Full Article

    Safety, Pharmacokinetics and Antiviral Activity of PGT121, a Broadly Neutralizing Monoclonal Antibody against HIV-1: A Randomized, Placebo-Controlled, Phase I Clinical Trial

    Researchers performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg–1 in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy.
    [Nature Medicine]

    Full Article

    The S100A10–AnxA2 Complex Is Associated with the Exocytosis of Hepatitis B Virus in Intrauterine Infection

    The authors investigated the mechanism as to how the hepatitis B virus virions pass through layers of the trophoblast.
    [Laboratory Investigation]

    Full Article

    Monoclonal Antibodies from Humans with Mycobacterium tuberculosis Exposure or Latent Infection Recognize Distinct Arabinomannan Epitopes

    The authors generated human IgG mAbs to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with M. tuberculosis.
    [Communications Biology]

    Full Article

    Explore Antibodies for Immunology Research
    REVIEWS

    Lessons in Self-Defence: Inhibition of Virus Entry by Intrinsic Immunity

    Investigators summarize what is known and what remains to be understood about the intrinsic factors that form the first line of defence against virus infection.
    [Nature Reviews Immunology]

    Full Article

    Characterization of SARS-CoV-2-Specific Humoral Immunity and Its Potential Applications and Therapeutic Prospects

    Scientists summarize the characteristics of the humoral immune response after SARS-CoV-2 infection and further emphasize the potential applications and therapeutic prospects of SARS-CoV-2-specific humoral immunity and the critical role of this immunity in vaccine development.
    [Cellular & Molecular Immunology]

    Full Article

    INDUSTRY AND POLICY NEWS

    Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase IIIb Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

    Arcturus Therapeutics Holdings, Inc. announced that the Vietnam Ministry of Health has approved initiation of the Phase IIIb part of the placebo-controlled, observer-blind Phase I/II/III clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern.
    [Arcturus Therapeutics Holdings, Inc.]

    Press Release

    Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the US FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

    Merck and Ridgeback Biotherapeutics announced that Merck has submitted an Emergency Use Authorization application to the FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
    [Merck (BusinessWire, Inc.)]

    Press Release

    FEATURED EVENT

    FSSCR French Society for Stem Cell Research

    November 9 – 10, 2021
    Montpellier, France

    > See All Events

    JOB OPPORTUNITIES

    Department Chair and Tenured Professor – Climate, Infectious Diseases and Pandemic Science

    University of Pittsburgh Graduate School of Public Health – Pittsburgh, Pennsylvania, United States

    Research Associate – Therapeutic Immunology & Infectious Disease

    University of Cambridge – Cambridge, England, United Kingdom

    Department Head – Microbiology, Immunology and Pathology

    Colorado State University – Fort Collins, Colorado, United States

    Immunoinformatician – Next Generation Vaccines against Infectious Diseases

    Vaccibody AS – Oslo, Norway

    Division Director – Infectious Diseases

    Vanderbilt University Medical Center – Nashville, Tennessee, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immunology of Infectious Disease News Twitter